Sam Isaly, OrbiMed Advisors founder, discusses health care industry stock picks.
Martin Shkreli, former CEO of Turing Pharmaceuticals, will appear in at the U.S. District Court in Brooklyn Tuesday following December's seven-count indictment, reports CNBC's Meg Tirrell.
GlaxoSmithKline CEO Andrew Whitty thinks his company's success has been a product of being patient and investing in innovation.
Sarepta Therapeutics shares soared Monday after the stock was upgraded to "outperform" at Oppenheimer.
Jesper Brandgaard, CFO of Novo Nordisk, discusses the pharmaceutical company's earnings results and the impact of the declining dollar.
Analysts expected Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.
Potential market cap swings in biotech with CNBC contributor Dan Nathan.
Sarepta was down sharply a day after an FDA advisory committee voted against recommending the company's Duchenne muscular dystrophy drug.
Discussing the play on Sarepta Therapeutics as its Duchenne muscular dystrophy drug sees pressure from FDA, with the FMHR traders.
CNBC's Meg Tirrell reports on the possibility of Perrigo CEO Joseph Papa heading over to Valeant, as well as biotech firm Interxon feeling some pressure after the release of a report calling it 'the new Theranos.'
Robert Greifeld, Nasdaq CEO, discusses bank earnings, the IPO market, and more at the eMerge Americas conference.
Federal regulators are investigating blood-testing start-up Theranos over whether it misled investors.
Adam Parker, Morgan Stanley chief U.S. equity strategist, thinks biotech and pharma look attractive, in discussing his market forecast.
Following his announcement to donate $250 million for cancer research, Sean Parker joined CNBC to discuss his initiative.
David Seaburg, Cowen & Company Head of Sales & Trading, and Tobias Levkovich, Citi Chief U.S. Equity Strategist, discuss the current state of the markets going into earnings season.
Discussing drug pricing, product approvals in the health care industry, and what's to come from the sector, with Matt Maley, Miller Tabak managing director & equity strategist, and Ian Somaiya, BMO Capital biotech analyst.
Is it time to buy biotech as the sector is breaking out?
The FMHR traders look at retail earnings, and the health of biotech stocks right now.
BehavioSec provides biometric security to customers. Its founder, Olov Renberg discusses fundraising and why banks are intrigued by BehavioSec’s product.
Les Funtleyder, E Squared Asset Management Portfolio Manager, and David Seaburg, Cowen & Company Managing Director and Head of Sales & Trading, discuss the biotech sector and how investors should approach it.